Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers With CDK4/6 Inhibitors

Using transgenic mouse models, cell line-based functional studies and clinical specimens, we show that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive breast cancer. This is overcome using CDK4/6 inhibitors. Inhibition of CDK4/6 not only suppresses Rb phosphorylation, but als...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Goel, Shom, Wang, Qi, Watt, April C., Tolaney, Sara M., Dillon, Deborah A., Li, Wei, Ramm, Susanne, Palmer, Adam C., Yuzugullu, Haluk, Varadan, Vinay, Tuck, David, Harris, Lyndsay N., Wong, Kwok-Kin, Liu, X. Shirley, Sicinski, Piotr, Winer, Eric P., Krop, Ian E., Zhao, Jean J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4794996/
https://ncbi.nlm.nih.gov/pubmed/26977878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.02.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados